References
- Ohm L, Lundqvist A, Dickman P, et al. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma 2014 Aug 20. [Epub ahead of print]
- Kantarjian H, O’Brien S. The chronic leukemias. In: Goldman L, Schafer A, Arend W, et al., editors. Cecil medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; 2012. pp 1209–1218.
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439–4442.
- Baslar Z. Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients. European Hematology Association Press Releases. Available from: www.ehaweb.org/news/press/eha-press-releases/article/81/do-generics-of-imatinib-jeopardize-patient-safety-for-the-sake-of-saving-money-an-experience-in-turkish-patients
- Soysal T, Eskazan AE, Ar MC. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Rev Hematol 2014 Oct 8. [Epub ahead of print]
- Eskazan AE, Elverdi T, Yalniz FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 2014 May 6. [Epub ahead of print]
- Eskazan AE, Ayer M, Kantarcioglu B, et al. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. Br J Haematol 2014;167:139–141.
- Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 2008;42:23–28.
- Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
- Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122: 515–522.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.